



Title	The Administration of Ciprofloxacin During Continuous Renal Replacement Therapy : Pilot Study
Author(s)	Hayakawa, Mineji; Fujita, Itaru; Iseki, Ken; Gando, Satoshi
Citation	ASAIO Journal, 55(3), 243-245 <a href="https://doi.org/10.1097/MAT.0b013e31819962b5">https://doi.org/10.1097/MAT.0b013e31819962b5</a>
Issue Date	2009-05
Doc URL	<a href="http://hdl.handle.net/2115/43035">http://hdl.handle.net/2115/43035</a>
Rights	This is a non-final version of an article published in final form in ASAIO Journal. 55(3):243-245, May/June 2009
Type	article (author version)
File Information	55-3_p243-245.pdf



[Instructions for use](#)

## Abstract

Continuous renal replacement therapy (CRRT) is a common technique in critically ill patients. However, there is no uniformity in the pharmacokinetics of ciprofloxacin (CPFX) used during CRRT. The aims of present study were to estimate the pharmacokinetics of CPFX and to determine the appropriate administration of CPFX for critically ill patients undergoing CRRT. CPFX total clearance ( $CL_{tot}$ ) was calculated based on the creatinine clearance ( $CL_{cre}$ ), dialysate flow ( $Q_D$ ) and ultrafiltrate flow ( $Q_F$ ) as follow:  $CL_{tot} (l/h) = (4.83 CL_{cre} (l/h) + 6.41) + 0.92 (Q_D+Q_F (l/h))$  base on *in vitro* study using CRRT circuit model. We administered CPFX to critically ill patients based on the  $CL_{tot}$ , which was  $50 \times CL_{tot} (l/h)$  (mg/day). We confirmed that the CPFX concentrations reached higher than optimal concentrations and the infections were all successfully controlled in these patients.

Continuous renal replacement therapy (CRRT) is a common technique to treat renal failure in critically ill patients. However, there is no uniformity in the pharmacokinetics of the drugs used during CRRT. Ciprofloxacin (CPFX) is used in the treatment for severe infections<sup>1</sup>. However, the pharmacokinetics of CPFX are affected by both the renal function and CRRT<sup>2,3</sup>. The aim of present study was to establish a wide use dosage-regimen method to calculate the optimal dosage for CPFX in critically ill patients during CRRT. For this purpose, we examined as follows: 1) estimated the CPFX total clearance ( $CL_{tot}$ ) during CRRT based on dialysate flows ( $Q_D$ ), the ultrafiltrate flows ( $Q_F$ ), and renal function of the patient, 2) determined the appropriate dose of CPFX based on the  $CL_{tot}$ , and 3) confirmed CPFX pharmacokinetics in critically ill patients receiving CRRT when the dose determined based on  $CL_{tot}$  was administered.

## **Materials and Methods**

### *1) To estimate $CL_{tot}$ during CRRT*

A CRRT system (ACH-10, Asahi Medical Co., Japan) was used. A CRRT circuit was set up using a cellulose triacetate hollow fiber 1.1 m<sup>2</sup> hemofilter (UT-110, Nipro, Japan). The machine was primed with a 5% bovine serum albumin (BSA) solution. Twenty mg of CPFX were added to 200 ml of the 5% BSA solution in the reservoir. The CRRT conditions were as follows: the BSA solution flow was fixed at 9 l/h;  $Q_D$  was defined from 0, 1, and 2 l/h;  $Q_F$  was defined from 0, 1, and 2 l/h independently of  $Q_D$ ; normal saline was used as a

dialysate and it also served as a replacement fluid which was infused post-dilusionally with an equal amount of  $Q_F$ . We took samples from the pre-hemofilter and the filtrates at 15, 30, 45, and 60 min after the start of CRRT. Each variation was performed twice and the clearance by CRRT ( $CL_{CRRT}$ ) was calculated 2 times based on  $Q_D$ ,  $Q_F$ , and CPFX concentrations in the filtrate and pre-hemofilter. The concentrations of CPFX were determined using the high-performance liquid chromatography method <sup>4</sup>.

CPFX clearance in patients ( $CL_{vivo}$ ) was based on the creatinine clearance ( $CL_{cre}$ ) in previous study <sup>2</sup>. The CPFX  $CL_{tot}$  in a patient during CRRT was calculated as follows:

$$\begin{aligned} \text{CPFX } CL_{tot} \text{ (l/h)} &= CL_{vivo} + CL_{CRRT} \\ &= (4.83 CL_{cre} \text{ (l/h)} + 6.41) + CL_{CRRT} \text{ (l/h)} \quad (1) \end{aligned}$$

## 2) To determine the appropriate dose of CPFX

Clinical success has been obtained when the target of the area under the plasma concentration-time curve (AUC)  $[(\text{mg/l})\cdot\text{h}]$  / minimum inhibitory concentration (MIC)  $(\text{mg/l}) \geq 100 \text{ (h)}$  <sup>5</sup>. In a majority of bacteria, the MIC required to inhibit the growth of 90% of the strains for CPFX was  $<0.5 \text{ mg/l}$  <sup>1</sup>. Therefore, we determined the target of AUC to be  $\geq 50 [(\text{mg/l})\cdot\text{h}]$ . We determined the optimal dose to be  $50 \times CL_{tot} \text{ (l/h)}$  (mg/day) in order to maintain the target of AUC based on the  $CL_{tot}$ .

## 3) To confirm CPFX pharmacokinetics in critically ill patients receiving CRRT

Three patients with acute renal failure were studied. **Table 1** shows the patients' clinical backgrounds. In all patients,  $CL_{tot}$  was calculated and the optimal CPMX doses determined based on the  $CL_{tot}$  were administered intravenously. A CRRT system (JUN600, UBE, Japan) was used. The same hemofilter as that used in the *in vitro* study was used. The dialysate and replacement fluid were Sublood-A<sup>®</sup> (Fuso, Japan). The CRRT conditions were as follows: The blood circuit pumped 6 l/h;  $Q_F$  was defined as 1.0 l/h in all patients;  $Q_D$  was infused in a countercurrent at rates of 1.0 l/h. The replacement fluid was infused after dilution as clinically indicated. The sampling points were pre-hemofilter and the filtrates. The samples were taken before the start of the next CPMX administration, at 1, 1.5, 2, 6, and 12 h after the start of the drug administration. The CPMX concentrations were determined by the high-performance liquid chromatography method <sup>4</sup>. A pharmacokinetic analysis was performed using the nonlinear least-squares regression program <sup>6</sup>. The parameters were calculated by a two-compartment open model with a constant rate of infusion. The AUC was calculated using the trapezoidal rule.

## Results

$CL_{CRRT}$  obtained by interpolation into a simple linear regression of  $CL_{CRRT}$  against  $Q_D+Q_F$  closely correlates with the experimental data (**Figure 1**). CPMX  $CL_{tot}$  was calculated as follows:

$$CL_{tot} (l/h) = (4.83 CL_{cre} (l/h) + 6.41) + 0.92 (Q_D + Q_F (l/h)) \quad (2)$$

$CL_{tot}$  in the patients were presented in **Table 1**. The CPF<sub>X</sub> doses in all patients were set 600 mg/day. CPF<sub>X</sub> at a dose of 300 mg was administered during a 60 min period every 12 h. The CPF<sub>X</sub> concentrations curve was presented in **Figure 2**. **Table 2** shows the pharmacokinetic parameters. The mean of actual AUC reached a level higher than the target AUC. The infections of the patients were successfully controlled.

## Discussion

Several reports have described the achievement of AUC/MIC  $\geq 100$  to demonstrate a good clinical outcome<sup>5</sup>. However, a high dose of CPF<sub>X</sub> is needed to achieve the target of AUC/MIC. Lipman *et al.*<sup>7</sup> concluded that an intravenous dosage of 400 mg 3 times daily was safe and effective in patients with severe sepsis. In a clinical study, we confirmed that the actual AUC [54.9 $\pm$ 12.8 (mg/l)·h] was higher than the targeted AUC [50 (mg/l)·h], when the CPF<sub>X</sub> amounts, based on the  $CL_{tot}$ , were intravenously administered. This result showed that the  $CL_{tot}$  formula as determined based on the findings of an *in vitro* study is therefore appropriate.

In CRRT, high-flux membranes with large pores and no drug-adsorption are recommended. The hemofilter used in this study was a cellulose tri-acetate membrane with the recommended characteristics. The pore size of the

hemofilter may not influence the  $CL_{CRRT}$  because of the sufficiently low molecular weight of CPMX<sup>1,4</sup>. The surface area of the hemofilter may affect the clearance of small solute when  $Q_D$  is large amount<sup>8</sup>. Therefore, the results of the present study are not considered to be adaptable to the follow situations: 1) the hemofilter has drug-adsorption ability; 2) when  $Q_D$  is a large amount, then the hemofilter has a much different surface area from that used in the present study.

In conclusion, we estimated  $CL_{tot}$  during CRRT based on  $Q_D$ ,  $Q_F$ , and renal function of the patient. We established a wide use dosage-regimen calculation of CPMX, which was  $50 \times [(4.83 CL_{cre} + 6.41) + 0.92 (Q_D+Q_F)]$  (mg/day) in critically ill patients during CRRT. Furthermore, we confirmed that the wide use dosage-regimen method is also appropriate in a clinical setting.

## References

1. Davis R, Markham A, Balfour JA: Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. *Drugs* 51: 1019-1074, 1996.
2. Shah A, Lettieri J, Blum R, et al: Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. *J Antimicrob Chemother* 38: 103-116, 1996.
3. Bohler J, Donauer J, Keller F: Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. *Kidney Int Suppl* 72: S24-S28, 1999.
4. Maya MT, Goncalves NJ, Silva NB, et al: Simple high-performance liquid chromatographic assay for the determination of ciprofloxacin in human plasma with ultraviolet detection. *J Chromatogr B Biomed Sci Appl* 755: 305-309, 2001.
5. Wright DH, Brown GH, Peterson ML, et al: Application of fluoroquinolone pharmacodynamics. *J Antimicrob Chemother* 46: 669-683, 2000.
6. Yamaoka K, Tanigawara Y, Nakagawa T, et al: A pharmacokinetic analysis program (multi) for microcomputer. *J Pharmacobiodyn* 4: 879-885, 1981.
7. Lipman J, Scribante J, Gous AG, et al: Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. *Antimicrob Agents Chemother* 42: 2235-2239, 1998.
8. Brunet S, Leblanc M, Geadah D, et al: Diffusive and convective solute

clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. *Am J Kidney Dis* 34: 486-492, 1999.

## Figure Legends

**Figure 1.** Cefepime clearance by CRRT based on an *in vitro* study. A simple linear regression analysis revealed a strong correlation between  $CL_{CRRT}$  and  $Q_D + Q_F$ . Circles indicate Cefepime  $CL_{CRRT}$  in each variation of CRRT settings. The line is the regression line.

**Figure 2.** The plasma Cefepime concentration-time curve at a Cefepime administration of 300 mg every 12 h. The circle and bar indicate the mean and standard deviation of Cefepime concentration.

**Table 1. Characteristics of the Patients**

Patient	Gender	Age (years)	Weight (kg)	APACHE-II	Urea nitrogen (mmol/l)	24-hour CL <sub>cre</sub> (l/h)	Predictive CL <sub>CRRT</sub> (l/h)	Predictive CL <sub>tot</sub> (l/h)
1	male	75	59	36	38	1.68	1.84	16.4
2	male	77	64	42	19	0.86	1.84	12.4
3	male	41	65	19	29	0	1.84	8.3
Mean ± SD		64 ± 20	62 ± 3	32 ± 12	29 ± 10	0.85 ± 0.84	1.84	12.4 ± 4.1

APACHE-II, Acute Physiology and Chronic Health Evaluation II score; CL<sub>cre</sub>, Creatinine clearance; CL<sub>CRRT</sub>, clearance by continuous renal replacement therapy; CL<sub>tot</sub>, total clearance.

**Table 2. Pharmacokinetic Parameters of Ciprofloxacin in the patients during Continuous Renal Replacement Therapy**

Patient	CL <sub>CRRT</sub> (l/h)	CL <sub>tot</sub> (l/h)	t <sub>1/2</sub> (h)	V <sub>ss</sub> (l)	AUC [(mg/l)·h]
1	1.78	14.6	4.93	99.1	42.1
2	1.81	6.3	9.74	85.7	54.8
3	1.75	5.4	10.9	82.7	67.8
Mean ± SD	1.77 ± 0.03	8.8 ± 5.1	8.52 ± 3.16	89.2 ± 8.7	54.9 ± 12.8

CL<sub>CRRT</sub>, clearance by continuous renal replacement therapy; CL<sub>tot</sub>, total clearance; t<sub>1/2</sub>, a half-life; V<sub>ss</sub>, steady state volume; AUC, Area under the concentration-time curve.



